Rashid Lui 雷諾信

#GIOncology @CUHKGI @CUHKMedicine • SME @JGHofficial • President #HKASLD • VP #HKSDO • @ASCO #ASCOLDP APAC Class 21-22 • @myESMO #ESMOLGP Asia Class 23-24

[Keith Siau @drkeithsiau]

An iPhone compatible endoscope with a diameter of 5.2mm and a 3.2mm working channel

[Rashid Lui 雷諾信 @RashidLui]

In our recent SRMA we found that dietary restriction implemented during active cancer treatment was associated with favourable treatment outcomes without evidence of increased toxicity or compromised quality of life.

Food for thought indeed!

https://t.co/dbRoOYeOXS

[Journal of Gastroenterology and Hepatology @JGHofficial]

Can a simple endoscopy-based score personalize upper GI cancer screening? 🎯📗 #TealJournal

The J-GESS score (Watanabe et al. 🇯🇵) predicts 5-year gastric cancer and ESCC risk using routine EGD data—age, sex, smoking, and gastric mucosal atrophy.

🔗 https://t.co/YCSoK0G7CQ

[Rashid Lui 雷諾信 @RashidLui]

Very unfortunate accident last week and ruptured my Achilles. Thanks so much @drsling and #LeoChiu for your great help at #CUHKMedicalCentre

Really sun fu sai wifey during these times. Kids have been very 乖 too

[Rashid Lui 雷諾信 @RashidLui]

Prof @DrLoomba sharing his insights on #MASLD at @CUHKMedicine @CUHKGI !

[Rashid Lui 雷諾信 @RashidLui]

Glad to learn from local and international experts during the chairing of various sessions. Also had the pleasure to share some updates on the role of ctDNA in GI cancers

Always a pleasure to meet friends, both old and new!

#IDDF2026 @CUHKMedicine

[Hong Jae Chon @hongjaechon]

❓ In real-world HCC practice, do patients ineligible for the HIMALAYA trial still benefit from durvalumab plus tremelimumab? @JGHofficial
👉 Trial-eligible patients had median OS of 19.4 vs. 15.4 months, but ineligible patients with preserved liver function (ALBI grade 1) achieved comparable survival. @APASLnews

👉 Multicenter retrospective study by Matono et al. has recently been published in Journal of Gastroenterology and Hepatology.
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Full text: https://t.co/Jxf613G9Ey
#HCC #LiverCancer #Immunotherapy #DurvalumabTremelimumab #RealWorldEvidence

[Rashid Lui 雷諾信 @RashidLui]

Excellent talks by @VWSWong and @RexWHHui on the management of chronic hepatitis B patients with #MAFLD or #diabetes

#HKASLD @CUHKMedicine

[Rashid Lui 雷諾信 @RashidLui]

@drkeithsiau Probably a cognitive bias

[CUHK Medicine @CUHKMedicine]

In the latest "Best Global Universities Subject Rankings 2026-27" released by the world university ranking body @usnews , @CUHKMedicine has once again secured the world's No. 2 position in "Gastroenterology & Hepatology," maintaining its place among the global top three for four consecutive editions.

[Herbert Loong, MBBS, FASCO @herbloong]

Some happy faces from 1st day of @myESMO #ESMOTATAsia26 in #HongKong.

Global drug development is a close knit community. All are welcome 🤗. Great to see everyone!

@CUHKofficial @CUHKMedicine @apoddc @BrigetteMa2 @RashidLui @ZaZa_Othman @jtgeorgy and many others 😀

[Rashid Lui 雷諾信 @RashidLui]

Honored to help host the Cross Border Expert Exchange by the Hong Kong Society of Digestive Oncology #HKSDO on “Defining the Role of Conversion Surgery in Molecularly Selected Advanced #ColorectalCancer” with experts from #SYSUCC

@CUHKMedicine

[Rashid Lui 雷諾信 @RashidLui]

Always a pleasure to meet the amazing @myESMO Asia team in #HongKong

#ESMOTATAsia26

[ESMO - Eur. Oncology @myESMO]

🙌 ESMO TAT Asia 2026 has officially begun. Over the next three days, experts across research and clinical oncology share the latest in translational science.

Join the #ESMOTATAsia26 conversation.

👉 https://t.co/mTXKFDzB7c

#ESMOMeetings #Oncology #CancerResearch

[ESMO - Eur. Oncology @myESMO]

👏 Congratulations to the #ESMOMeritAward recipients at #ESMOTATAsia26.
These young researchers were recognised for the scientific merit of their abstracts
➡️ https://t.co/rarmwhvz9B

[Journal of Gastroenterology and Hepatology @JGHofficial]

How is the GI cancer burden changing across Asia-Pacific? 🌏🎗️ #TealJournal

A new review highlights regional differences in GI cancer incidence and mortality across Asia-Pacific, reflecting variations in screening, healthcare access, and outcomes 📊🔬

🔗 https://t.co/6PvHUhRqwS

[Rashid Lui 雷諾信 @RashidLui]

Excellent sharing by Prof Xu Ruihua on emerging molecular targets and drugs for Asian prevalent cancers, focusing on gastric cancer

Many new drugs in the pipeline, especially from China

#ESMOTATAsia26

[Rashid Lui 雷諾信 @RashidLui]

Opening by Prof @BrigetteMa2 of @myESMO TAT Asia 2026

@CUHKMedicine

[Rashid Lui 雷諾信 @RashidLui]

Our latest study showed that the mucosal #microbiome of right-sided colorectal cancer #CRC was distinctly different from that of left-sided CRC patients.

@CUHKMedicine

https://t.co/lR2Hfntg8h